The pandemic has brought us all a renewed appreciation of biomedical innovation, so it was good to see 2021 emerge as such a big year for biotech investment and IPOs. In addition to more money directed to this space, financial and technological innovations, more commonly found outside the biomedical sphere, are tapping into larger capital flows and improving business efficiencies. What trends should investors be tracking, and how can more funds be directed toward underinvested but high-need areas of research?
Research Reporter, STAT News
Chairman, Bellco Capital
Partner, Jumpstart Nova
Head of Sandbox AQ
Executive Vice President and Vice Chairman, Royalty Pharma
Co-Founder and Managing Director, ARCH Venture Partners